Gynaecological Oncology Nursing
Comprehensive clinical reference for GCC nurses covering gynaecological malignancies, surgical care, chemotherapy management, radiotherapy, survivorship, and exam preparation. Evidence-based. Aligned with DHA, DOH, and SCFHS competency frameworks.
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Brachytherapy
PARP Inhibitors
Lymphoedema
Survivorship
GCC Context
Key Principle Gynaecological cancers collectively affect the ovary, endometrium, cervix, vulva, vagina, and trophoblastic tissue. Early diagnosis is challenged by non-specific symptoms (ovarian cancer) and cultural barriers (GCC context).
Ovarian Cancer
Epidemiology & Lethality
- Most lethal gynaecological cancer — ~70% present at advanced stage (III/IV)
- Late presentation driven by non-specific, insidious symptoms
- Spreads via peritoneal dissemination (trans-coelomic spread) to omentum, bowel, diaphragm
- 5-year survival stage I: ~90%; stage IV: ~20–30%
Risk Factors
- BRCA1/BRCA2 mutation — lifetime risk up to 44% (BRCA1) / 17% (BRCA2)
- Lynch syndrome (mismatch repair gene mutations)
- Nulliparity / infertility
- HRT (combined, long-term use — modest increase)
- Family history of ovarian/breast cancer
- Protective: OCP use, breastfeeding, tubal ligation, BSO
Clinical Presentation (Non-Specific)
- Persistent bloating / abdominal distension
- Abdominal or pelvic pain
- Early satiety / difficulty eating
- Urinary frequency or urgency
- Symptoms >12 times/month → investigation indicated (NICE guidance)
- Advanced: ascites, pleural effusion, bowel obstruction
Diagnosis & FIGO Staging
- CA-125 + transvaginal USS — not a screening tool (insufficient sensitivity/specificity)
- CT chest/abdomen/pelvis for staging
- Stage I: confined to ovary/ovaries
- Stage II: pelvic extension
- Stage III: peritoneal metastases / retroperitoneal nodes (most common at diagnosis)
- Stage IV: distant metastases (pleural effusion, liver parenchyma, etc.)
- HE4 can complement CA-125 in diagnosis
Endometrial Cancer
Epidemiology & Presentation
- Most common gynaecological cancer in Western countries
- Rising incidence in GCC due to obesity epidemic and metabolic syndrome
- Post-menopausal bleeding (PMB) = investigate until proved otherwise
- TVS endometrial thickness >4 mm in PMB → pipelle biopsy indicated
- Pre-menopausal: irregular/heavy bleeding, especially with risk factors
Risk Factors
- Obesity (excess peripheral oestrogen from adipose aromatase)
- Type 2 diabetes / insulin resistance
- PCOS
- Nulliparity
- Unopposed oestrogen HRT (without progestogen)
- Tamoxifen use (breast cancer treatment — endometrial effect)
- Lynch syndrome (highest hereditary risk)
Type 1 vs Type 2 Endometrial Cancer
| Feature | Type 1 (Endometrioid) | Type 2 (Serous / Clear Cell) |
|---|
| Histology | Endometrioid adenocarcinoma | Serous, clear cell, carcinosarcoma |
| Driver | Oestrogen-driven | Not oestrogen-dependent |
| Prognosis | Better (often early stage) | Worse — aggressive, deep invasion |
| Grade | G1–G2 predominantly | G3 / high-grade |
| Molecular | PTEN, KRAS, MSI-H mutations | TP53 mutation, HER2 amplification |
Other Gynaecological Cancers
Cervical Cancer
- HPV-driven (types 16 and 18 account for ~70%)
- Screened via Pap smear / colposcopy
- Presentation: IMB, PCB, vaginal discharge
- Treatment: radical hysterectomy (early) / chemoradiotherapy (locally advanced)
- HPV vaccination (Gardasil) — preventive; available in GCC school programmes
Vulval Cancer
- Predominantly squamous cell carcinoma (~90%)
- Risk factors: HPV, lichen sclerosus, VIN (vulval intraepithelial neoplasia)
- Presentation: lump, persistent itch, ulceration, bleeding
- Often delayed diagnosis — embarrassment / cultural factors in GCC
- Treatment: wide local excision ± inguinal lymph node dissection ± RT
Gestational Trophoblastic Disease
- Spectrum: hydatidiform mole → invasive mole → choriocarcinoma
- hCG is both a diagnostic and surveillance marker
- Complete molar pregnancy: 46XX, diploid, no fetal tissue
- Choriocarcinoma: highly chemosensitive (methotrexate / EMA-CO regimen)
- Monitoring: serial hCG until normalisation; contraception during surveillance
Vaginal Cancer
- Rare — primarily squamous cell carcinoma (associated with HPV)
- Clear cell adenocarcinoma historically linked to in-utero DES exposure
- Presentation: vaginal discharge, bleeding, mass
- Treatment: radiotherapy (primary modality) ± surgery for early lesions
VTE Risk Alert Gynaecological cancer patients undergoing major surgery are classified as VERY HIGH thrombotic risk. Extended LMWH prophylaxis for 28 days post-surgery is recommended (NICE NG89 / ACOG guidance).
Ovarian Cancer Surgery
Staging Laparotomy / Primary Cytoreductive Surgery
Goal: optimal cytoreduction (residual disease <1 cm, ideally R0). Extent of surgery correlates with survival.
| Component | Purpose | Nursing Considerations |
|---|
| Total Abdominal Hysterectomy + BSO | Remove primary tumour | Pre-op counselling re: surgical menopause if premenopausal |
| Omentectomy | Remove omental disease (common site of spread) | Risk of prolonged post-op ileus — NG tube / bowel care |
| Pelvic & Para-aortic Lymphadenectomy | Nodal staging and debulking | Lymphoedema risk; drain management |
| Peritoneal biopsies / cytology | Staging — FIGO classification | Document all biopsy sites; specimen labelling critical |
| Bowel resection (if indicated) | Debulk bowel disease | Stoma formation possible — pre-op stoma siting, BCNS referral |
Cervical Cancer Surgery — Radical (Wertheim's) Hysterectomy
Procedure & Key Differences
- Removes uterus, cervix, upper 1/3 vagina, parametrium, cardinal ligaments
- Pelvic lymph node dissection included
- Ureters are dissected free (ureterolysis) — risk of ureteric injury/fistula
- Bladder is mobilised — disruption of autonomic nerve supply
- Nerve-sparing technique aims to preserve bladder function
Post-operative Bladder Dysfunction
- Neuropraxia of pelvic autonomic nerves → voiding dysfunction
- Urinary retention most common: TWOC protocol (trial without catheter)
- Patient taught CISC (clean intermittent self-catheterisation) if retention persists
- Catheter usually left in situ 7–14 days post-operatively
- Urine output monitoring, residual volume checks, UTI prevention
- Refer to continence nurse / urology if not resolving at 6–8 weeks
Vulvectomy
Procedure Types
- Simple vulvectomy: removes vulval skin only (for VIN/pre-malignant)
- Radical vulvectomy: deep excision of vulval tissue + bilateral inguinal-femoral lymphadenectomy
- Skin graft may be required for large defects
- Sentinel lymph node biopsy (SLNB) for unifocal lesions <4 cm without suspicious nodes
Wound Care Challenges
- Vulval wound breakdown: HIGH risk — warm, moist, contaminated perineal environment
- Twice-daily wound inspection; gentle irrigation (normal saline or warm water)
- Catheter in situ to divert urine from wound
- Low-residue diet to reduce faecal contamination; stool softeners
- Skin graft: immobilisation, pressure dressing, graft viability monitoring (5–7 days)
- Body image: significant psychological impact — specialist nursing support
Post-operative Nursing: All Major Gynaecological Surgery
General Post-op Care
- Haemodynamic monitoring: BP, HR, urine output ≥0.5 ml/kg/hr
- Pain: multimodal analgesia (epidural/PCA/paracetamol/NSAIDs)
- Drain management: document volume, character; drain removal criteria
- Wound inspection: redness, dehiscence, haematoma, infection signs
- Early mobilisation — VTE prophylaxis + pulmonary benefit
- LMWH: begin 12 hours post-op, continue 28 days post-major gynaecological cancer surgery
- TED stockings if not contraindicated
Bowel Care Post-omentectomy
- Omentectomy + bowel handling → prolonged ileus common (3–5+ days)
- NBM until bowel sounds return / flatus passed
- NG tube decompression if distension or vomiting
- ERAS (Enhanced Recovery After Surgery) protocol in gynaecological oncology
- ERAS elements: oral carbohydrate loading, early oral fluids, early ambulation, minimise IV fluids
- Ileus vs bowel obstruction: differentiate clinically and radiologically
Urostomy / Parastomal Care (when urinary diversion required)
- Urinary diversion (ileal conduit) required for bladder involvement or fistula formation
- Pre-operative stoma siting by BCNS (bowel/stoma care nurse specialist)
- Post-op: urostomy pouch management, urinary mucus (normal from ileal conduit), stent in situ initially
- Peristomal skin care: prevent maceration/contact dermatitis
- Patient education: pouch change, signs of UTI, night drainage
- Psychological support: altered body image, sexuality concerns
ERAS Protocol in Gynaecological Oncology Evidence shows ERAS pathways reduce length of stay by 1–2 days, reduce post-operative complications, and improve patient experience. Key elements: minimise fasting time, early oral intake, multimodal analgesia, early catheter removal, early mobilisation. Requires multidisciplinary collaboration (nurse, surgeon, anaesthetist, dietitian).
Carboplatin Dosing Carboplatin is dosed by AUC (area under curve) using the Calvert formula: Dose (mg) = AUC × (GFR + 25). Requires accurate GFR — use EDTA/isotope GFR or validated creatinine clearance. Renal function MUST be checked before each cycle.
Ovarian Cancer — First-Line Chemotherapy
Carboplatin + Paclitaxel (Standard Regimen)
- Carboplatin AUC 5–6 IV + Paclitaxel 175 mg/m² IV — 3-weekly for 6 cycles
- Alternatively: dose-dense weekly paclitaxel 80 mg/m² (Japanese JGOG trial data)
- Intraperitoneal (IP) chemotherapy: delivers higher local drug concentration directly to peritoneal cavity; used post-optimal cytoreduction; requires IP port; associated with greater toxicity but improved PFS in selected patients
- NEOADJUVANT chemotherapy followed by interval debulking surgery: for patients unfit for primary surgery or suboptimal candidates
Paclitaxel — Side Effects & Management
- Peripheral neuropathy (PN): cumulative, dose-limiting; Grade 1 (mild) → grade 4 (disabling). Assess with each cycle. Grade 2+ sensory → 25% dose reduction; Grade 3+ → hold/stop
- Hypersensitivity reaction (HSR): Cremophor EL excipient. PREMEDICATION: dexamethasone 20 mg IV + chlorphenamine 10 mg IV + ranitidine 50 mg IV (or equivalent H2 blocker). Infuse slowly first 15 min. Grade 1–2 HSR: pause, manage, re-challenge slowly. Grade 3–4: stop permanently
- Alopecia: scalp cooling (Paxman/Digni cap) reduces risk; discuss prior to cycle 1
- Myalgia/arthralgia: onset 48–72h post-infusion; paracetamol/NSAIDs; hot compresses
Carboplatin — Side Effects & Monitoring
| Toxicity | Timing | Nursing Action |
|---|
| Thrombocytopenia | Nadir day 14–21 | FBC check D21 before next cycle; platelet transfusion if <20 × 10⁹/L or bleeding; neutropenia precautions |
| Anaemia | Cumulative | Fatigue assessment; Hb threshold for transfusion per local policy (usually <80 g/L) |
| Nausea/vomiting | Acute (0–24h) and delayed (24–120h) | 5-HT3 antagonist + dexamethasone + NK1 antagonist (aprepitant) for moderately/highly emetogenic regimens |
| Renal impairment | Cumulative | Calvert formula dosing — GFR before every cycle; adequate pre/post hydration |
| Carboplatin hypersensitivity | Later cycles (cycle 5+, cumulative platinum exposure) | Have emergency kit available; consider desensitisation protocol if reaction occurs |
Maintenance Therapy — PARP Inhibitors
Olaparib / Niraparib — BRCA-Mutated & HRD-Positive Ovarian Cancer
Indications
- Olaparib: first-line maintenance (BRCA1/2 mutated) — SOLO-1 trial
- Niraparib: first-line maintenance regardless of BRCA status (PRIMA trial — HRD positive)
- Subsequent maintenance after platinum-sensitive relapse
- Oral daily tablets — outpatient management
Side Effects & Nursing
- Bone marrow suppression: FBC at baseline, monthly for 3 months then 3-monthly
- Nausea: take with food; antiemetics as needed
- Fatigue: pacing, sleep hygiene, exercise tolerance
- Risk of MDS/AML (rare but serious — check FBC regularly)
- Dose interruption/reduction per manufacturer guidance for toxicity
Bevacizumab (Anti-VEGF)
Bevacizumab — Key Nursing Concerns
- Hypertension: weekly BP monitoring mandatory; antihypertensives as needed; withhold if BP >160/110 despite treatment
- Proteinuria: urinalysis each cycle; if 2+ → 24-hour urine protein; withhold if >2g/24h
- Bowel perforation: rare but life-threatening; present as acute abdomen, peritonitis. HOLD bevacizumab 4–8 weeks before elective surgery
- Wound healing: do not use within 28 days of surgery; impairs angiogenesis
- Arterial thromboembolism: MI, stroke risk — report chest pain, neurological changes immediately
- Infusion reactions: less common than taxanes; observe for 60 min after first infusion
- Fistula formation: tracheo-oesophageal, GI, GU — report any fistula symptoms
Endometrial Cancer Chemotherapy
Standard Regimens
- Adjuvant: carboplatin + paclitaxel (same dosing as ovarian)
- Lenvatinib + pembrolizumab: 2nd-line recurrent/advanced endometrial cancer (KEYNOTE-775)
- Lenvatinib: hypertension, diarrhoea, fatigue, proteinuria, hepatotoxicity — monitor closely
Immunotherapy — MMR-Deficient Tumours
- Pembrolizumab (PD-1 inhibitor) / Dostarlimab for MSI-H / MMR-deficient endometrial cancer
- Immune-related adverse events (irAE) — nurse monitoring essential
- Colitis: diarrhoea, blood/mucus — hold immunotherapy, IV steroids
- Pneumonitis: new cough/SOB — CXR/CT, hold treatment, steroids
- Hepatitis: rising transaminases (LFTs weekly initially)
- Endocrinopathies: thyroiditis, hypophysitis, adrenal insufficiency — TFTs, cortisol, glucose
- Any grade 3+ irAE: hold immunotherapy, high-dose steroids, specialist review
Vaginal Dilation — Critical Post-RT Intervention Regular vaginal dilation must commence from approximately 4 weeks post-radiotherapy. Without it, vaginal stenosis and adhesions form rapidly, leading to dyspareunia, fistula risk, and inability to examine for recurrence. Requires sensitive, culturally appropriate patient education.
External Beam Radiotherapy (EBRT) — Pelvic Field
Planning & Delivery Process
- Simulation CT: patient immobilised in mould/wing board; bladder filling protocol (typically comfortably full for reproducibility)
- Planning CT with IV contrast; target volumes defined by radiation oncologist
- Skin tattoos (3 permanent ink dots): align patient precisely each fraction
- Typical dose: 45–50.4 Gy in 25–28 fractions (daily Monday–Friday)
- Treatment duration: ~5 weeks; linear accelerator (LINAC)
- IMRT (intensity modulated RT) reduces bowel/bladder dose compared to 3D-CRT
- Daily nursing role: patient assessment, side effect management, psychological support
Concurrent Chemoradiation (CRT)
- Standard for locally advanced cervical cancer (FIGO IB2–IVA)
- Weekly cisplatin 40 mg/m² concurrent with EBRT
- Cisplatin SE during CRT: nausea/vomiting, nephrotoxicity (aggressive hydration pre- and post-), peripheral neuropathy, ototoxicity
- Combined toxicity with RT: exacerbated mucositis, diarrhoea, fatigue
- Weekly FBC: cisplatin + RT → additive bone marrow suppression
- Treatment break policy: if grade 3+ toxicity, pause RT (impacts tumour control)
Acute Radiotherapy Side Effects
Radiation Cystitis
- Dysuria, urgency, frequency, haematuria
- Exclude UTI (urine MC&S first)
- Hydration: 2–2.5 L/day
- Avoid caffeine/alcohol/spicy foods
- Bladder instillations if severe
- Usually resolves 4–8 weeks post-RT
Radiation Proctitis
- Diarrhoea (grade 1–4), rectal urgency, rectal bleeding, tenesmus
- Low-residue diet during treatment
- Loperamide for diarrhoea management
- Topical steroids (hydrocortisone suppositories) for rectal inflammation
- Sucralfate enemas for bleeding (acute proctitis)
- CTCAE grading: Grade 3+ → consider treatment break
Skin & Vaginal Reactions
- Skin reaction: grade 1 (erythema) → grade 4 (ulceration/necrosis)
- Aqueous cream / prescribed barrier cream twice daily
- Avoid tight clothing, friction, sun exposure
- Vaginal mucositis: discharge, discomfort, odour
- Hygiene: warm water only; avoid douching
- Topical analgesia/lidocaine gel for severe mucositis
Late Radiotherapy Effects
Bowel Late Effects (6–24 months post-RT)
- Stricture: fibrosis of bowel lumen; symptoms: altered bowel habit, obstruction
- Bowel obstruction: nausea, vomiting, absolute constipation — surgical emergency
- Fistula: rectovaginal or vesicovaginal fistula — faeces/urine per vagina, highly distressing
- Management: colorectal/urology MDT; stoma formation may be required
- Chronic radiation enteropathy: malabsorption, bacterial overgrowth, nutritional support
- Nurse role: recognise late symptoms; many patients not followed up long-term in GCC
Bladder & Lymphatic Late Effects
- Radiation cystitis (late): haematuria — cystoscopy, hyperbaric oxygen in specialist centres
- Reduced bladder capacity: frequency, urgency — urodynamics, anticholinergic therapy
- Lymphoedema: pelvic/lower limb — pelvic node irradiation disrupts lymphatic drainage
- Vaginal stenosis: fibrosis, adhesions — progressive without dilation programme
- Bone: insufficiency fractures (sacral, pubic) — pelvic pain 6–24 months post-RT; MRI diagnosis
- Secondary malignancy (very long-term, rare): rectal, bladder cancer in RT field
Brachytherapy
Types & Applications
- Intracavitary brachytherapy: applicator inserted into vaginal vault (ring/ovoid applicators) or cervix (Fletcher tandem-and-ring system)
- PDR (Pulsed Dose Rate): continuous low-dose pulses over 1–2 days; patient admitted, applicator in situ throughout
- HDR (High Dose Rate): multiple outpatient fractions, each 10–15 min; applicator inserted/removed each visit
- Vault brachytherapy (post-hysterectomy): treats vaginal vault post-endometrial cancer surgery
- Interstitial brachytherapy: needles directly into tumour for bulky disease
PDR Brachytherapy Nursing (Applicator In Situ)
- Patient confined to bed for duration (radiation protection — nursing at distance)
- Radiation precautions: time-distance-shielding principles; limited visitor time; lead shield at bedside
- Urinary catheter in situ — prevent displacement of applicator; monitor output
- Analgesia: applicator causes significant discomfort — regular + PRN opioid analgesia
- Bowel: low-residue diet pre-procedure; anti-diarrhoeal if needed
- Applicator check: observe for displacement, verify position; radiographer/oncologist to review
- DVT prophylaxis: immobile patient — LMWH + TED stockings
- Psychological support: applicator experience distressing; communicate regularly from doorway
GCC Survivorship Context Specialist survivorship services are limited in many GCC centres. Cultural barriers exist around discussing sexual health, menopause, and psychosexual concerns. Nurses play a key role in normalising these conversations and signposting appropriate support.
Surgical Menopause
Post-BSO Menopause
- Immediate onset following bilateral salpingo-oophorectomy (BSO) in premenopausal women
- Abrupt oestrogen withdrawal → severe vasomotor symptoms (hot flushes, night sweats)
- More severe than natural menopause due to sudden hormone withdrawal
- Also: sleep disturbance, mood changes, cognitive effects, reduced libido
- Long-term: accelerated bone loss (osteoporosis), cardiovascular risk if not managed
- DEXA bone density scan recommended; calcium + vitamin D supplementation
HRT Considerations by Cancer Type
| Cancer | HRT | Evidence |
|---|
| Ovarian | Generally safe | Non-hormone-dependent; observational data reassuring |
| Cervical (SCC) | Safe | Not hormone-sensitive |
| Endometrial | Controversial | Individualised decision; evidence limited but early-stage low-grade may be acceptable |
| Breast (concurrent) | Contraindicated | Hormone-sensitive tumours |
Lymphoedema Management
Pelvic & Lower Limb Lymphoedema
Assessment
- Stemmer's sign: inability to pinch skin at base of 2nd toe (positive = lymphoedema)
- Heaviness, aching, tightness of legs/genitalia/lower abdomen
- Limb circumference measurement at defined landmarks
- Grade 1–4 (ISL staging): reversible pitting → irreversible fibrotic changes
- Causes: inguinal/pelvic LN dissection + pelvic RT = cumulative risk
CDT (Complete Decongestive Therapy)
- MLD (Manual Lymphatic Drainage): skilled lymphoedema therapist
- Compression garments: measured and fitted correctly (class 1–3)
- Skin care: intact skin, moisturise, avoid trauma/infection (cellulitis risk)
- Exercise: swimming, walking, Pilates — activates muscle pump
- Cellulitis: systemic antibiotics (penicillin) promptly — worsens lymphoedema
- Avoid: tight clothing, extremes of temperature, prolonged dependency
Sexual Health & Psychosexual Wellbeing
Vaginal Health Interventions
- Vaginal dilation programme: commence 4 weeks post-RT; 3× per week minimum; graduated dilators; prevents stenosis and enables surveillance examinations
- Local oestrogen (vaginal cream/pessary/ring): for vaginal atrophy/dryness — generally safe post-RT and in non-hormone-sensitive cancers
- Non-hormonal lubricants: water-based for intercourse; long-acting vaginal moisturisers (Replens) for atrophy symptoms
- Dyspareunia: assess cause (atrophy/stenosis/psychological); treat specifically
Psychosexual & Psychological Support
- Reduced libido: multifactorial (menopause/fatigue/psychological/relationship); testosterone patches (off-label, limited evidence post-cancer)
- Psychosexual counselling: PLISSIT model (Permission, Limited Information, Specific Suggestions, Intensive Therapy)
- Body image concerns: hair loss, stoma, vulvectomy, weight changes — specialist nurse support
- Cancer-specific anxiety: fear of recurrence (FOR) — prevalent in gynaecological cancer survivors; mindfulness-based interventions, CBT
- GCC context: discussions about sexual health often taboo; same-gender healthcare provider preferred; involve spouse sensitively
Fertility Preservation
Options Before Chemotherapy or Pelvic RT
- Oocyte cryopreservation: single woman — viable in GCC jurisdictions
- Embryo cryopreservation: married women — most established method; requires 2 weeks stimulation before chemotherapy
- Ovarian tissue cryopreservation: experimental; reimplantation post-treatment (risk of reintroducing malignant cells in some cancers)
- GnRH agonist co-treatment during chemotherapy: may protect ovarian reserve; limited evidence for ovarian cancer
- Ovarian transposition (oophoropexy): surgical repositioning of ovaries out of pelvic RT field before pelvic radiotherapy
- Trachelectomy: radical trachelectomy preserving uterus for early cervical cancer in women desiring fertility
- Islamic permissibility: embryo cryopreservation within marriage is permissible; BRCA testing and risk-reducing surgery = accepted principle; consult local religious authority for individual cases
- Oncofertility specialist referral: before any gonadotoxic treatment begins
GCC Clinical Context Late presentation of gynaecological cancers in the GCC is driven by cultural barriers to gynaecological examination, lack of population-wide screening for ovarian and endometrial cancer, and limited patient health literacy around non-specific symptoms. BRCA testing services are growing in UAE, KSA, and Qatar.
GCC-Specific Clinical Issues
- Ovarian cancer: no screening programme; most diagnose stage III–IV; late presentation = poorer outcomes vs Western cohorts
- Endometrial cancer: rising incidence parallels GCC obesity epidemic; type 2 diabetes prevalence is highest globally in Gulf states
- Cervical cancer: lower incidence in GCC vs global average (cultural factors, lower sexual behaviour exposure); HPV vaccine uptake variable
- BRCA testing: expanded carrier testing in high-risk families; some centres offer population-based BRCA screening
- Cultural barriers: modesty during examination; preference for female clinicians; stigma around cancer discussion; family information-sharing norms
- Survivorship: limited specialist survivorship clinics; sexual health conversations often not initiated in clinical practice
Regulatory & Exam Frameworks
- DHA (Dubai Health Authority): nurses must demonstrate chemotherapy administration competency; safe handling of cytotoxics
- DOH (Department of Health Abu Dhabi): oncology nursing scope includes education, assessment, and symptom management in cancer care
- SCFHS (Saudi Commission for Health Specialties): oncology nursing specialist exam covers pharmacology, side effect management, radiation safety
- Key exam topics: CTCAE grading, chemotherapy premedication, brachytherapy nursing, radiation safety principles, VTE prophylaxis in cancer, immunotherapy irAE management
- Professional development: EONS (European Oncology Nursing Society) and ONS (Oncology Nursing Society) resources widely used in GCC
10 MCQ Practice Questions
Gynaecological Chemotherapy Toxicity Tracker